Relmada Therapeutics, Inc. RLMD
4.16 USD -0.27 (-6.09%)
At closeNov 12, 2026, 4:20 PM EST
4.50 +0.34 +8.17%
After hours · Nov 12, 4:20 PM ET
4.14 Day range 4.47
3.07 52-week range 8.00
- YTD
- -13.87%
- 1 year
- +6.39%
News
benzinga.com Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call Relmada Therapeutics (NASDAQ:RLMD) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
benzinga.com Alpha Buying: 4 Biotech Stocks Insiders Are Betting On I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
benzinga.com Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. This is a 63.33 percent increase over losses of…
benzinga.com Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today
benzinga.com Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
benzinga.com This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Check out analysts' views on TRNO, RLMD, TLN, IMMX, CEG.
benzinga.com HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12 HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.
benzinga.com Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock jumped 11.73%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Hewlett Packard Enterprise Posts Blowout Q2 Earnings, Joins Marvell Technology And Other Big Stocks Moving Higher In Tuesday's Session US stock futures surge on tech sector news, HPE reports strong earnings, and other tech stocks follow suit in pre-market trading.- benzinga.com Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval On May 28, 2026, Relmada Therapeutics, Inc. (the "Company") filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number…
benzinga.com Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed RELMADA THERAPEUTICS, INC.COMMON STOCKPREFERRED STOCKWARRANTSSUBSCRIPTION RIGHTSDEPOSITARY SHARESPURCHASE CONTRACTSUNITSThis prospectus relates to common stock, preferred stock, warrants,…- benzinga.com Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call
- benzinga.com Relmada Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 62.07 percent increase over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12 Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Overweight rating and announces Price Target of $12.
benzinga.com Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19 Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.- benzinga.com Relmada Therapeutics Q4 EPS $(0.27) Misses $(0.14) Estimate Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.14) by 92.86 percent. This is a 56.45 percent increase over losses…
- benzinga.com Earnings Scheduled For March 19, 2026
benzinga.com FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving lower in pre-market trading.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
benzinga.com Why Is Relmada Therapeutics Stock Soaring Monday? Relmada Therapeutics shares rise on promising interim data from Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Market-Moving News for March 9th HIMS: 54% | Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report RLMD: 80% | Relmada Therapeutics Announces 12-month Interim Data From Its- benzinga.com Relmada Therapeutics Announces Private Placement Of $160M Pursuant to the terms of the securities purchase agreement, Relmada is selling an aggregate of (i) 29,474,569 shares of its common stock ("Common Stock") at a purchase price of $4.75 per share and…
- benzinga.com Relmada Therapeutics Announces 12-month Interim Data From Its Ongoing Phase 2 Trial Of NDV-01 For High-risk Non-muscle Invasive Bladder Cancer Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any…
benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14 LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $14.- benzinga.com Leerink Partners Upgrades Relmada Therapeutics to Outperform, Announces $8 Price Target Leerink Partners analyst Andrew Berens upgrades Relmada Therapeutics (NASDAQ:RLMD) from Market Perform to Outperform and announces $8 price target.
- benzinga.com Relmada Therapeutics Receives Written Feedback from FDA Regarding NDV-01 In Second-Line Refractory, High-Grade BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ In its written response to Relmada's Type B pre-IND submission, the FDA indicated that a single-arm, open-label clinical trial in this high-grade, BCG-unresponsive with CIS population is an…
benzinga.com This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Jefferies Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $9 Jefferies analyst Farzin Haque initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $9.
- benzinga.com Relmada Therapeutics To Present 6-Month Follow-Up Data From Ongoing Phase 2 Study Of NDV-01 In Development For Non-Muscle Invasive Bladder Cancer, At SUO 2025 Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safetyRelmada plans to advance NDV-01, a…
- benzinga.com Mizuho Upgrades Relmada Therapeutics to Outperform, Raises Price Target to $10 Mizuho analyst Uy Ear upgrades Relmada Therapeutics (NASDAQ:RLMD) from Neutral to Outperform and raises the price target from $1 to $10.
- benzinga.com Relmada Therapeutics Q3 EPS $(0.30) Misses $(0.04) Estimate Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.04) by 650 percent. This is a 58.33 percent increase over losses…
- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com A Glimpse of Relmada Therapeutics's Earnings Potential - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For May 12, 2025